Medical

Disappointing data from a Phase 1 study of intranasal delivery of AstraZeneca's ChAdOx1 nCoV-19 vaccine against COVID-19 led researchers from the University of Oxford to conclude that there is a "need for further development of nasal spray vaccines," the university said. The researchers reported the results in The Lancet's eBioMedicine. Intranasal delivery of the … [Read more...] about Intranasal delivery of AstraZeneca’s COVID-19 vaccine fails to elicit sufficient immune response in Phase 1 trial

United Therapeutics has announced the initiation of the Phase 3 TETON 2 trial of Tyvaso treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis (IPF). In December 2020, the company announced that the FDA had granted orphan drug designation to treprostinil for the treatment of IPF and had cleared an IND for the Phase 3 TETON program. The TETON 1 … [Read more...] about United Therapeutics announces the initiation of a second Phase 3 trial of Tyvaso in IPF patients

Synairgen has announced that the Phase 2 ACTIV-2 trial of SNG001 inhaled interferon-beta-1a in non-hospitalized COVID-19 patients failed to show a statistically significant reduction in hospitalization, viral load, safety, or resolution of symptoms compared to placebo, but the study did demonstrate a relative reduction of 86% in hospitalization. Over the course of the … [Read more...] about Synairgen announces top-line data from Phase 2 ACTIV-2 trial of SNG001 nebulized interferon-beta-1a for mild-to-moderate COVID-19

Odyssey Health announced that it has completed its Phase 1 study of PRV-002, a novel intranasal synthetic neurosteroid powder formulation that the company is developing for the treatment of concussion, and said that the results support advancing PRV-002 into Phase 2 trials. Odyssey acquired PRV-002 from Prevacus in January 2021. The company recently announced that the … [Read more...] about Odyssey Health says Phase 1 results for PRV-002 intranasal therapy for concussion support advancing the nasal powder to Phase 2

According to Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine has received a two-year $795,000 grant from the Alzheimer’s Association to support a Phase 2 trial of empagliflozin and intranasal insulin for Alzheimer's disease. The trial will be led by Wake Forest professor Suzanne Craft, who is director of the Alzheimer's Disease Research … [Read more...] about Wake Forest University School of Medicine gets Alzheimer’s Association grant for Phase 2 trial of intranasal insulin

On a form 8-k filed with the US Securities and Exchange Commission (SEC), United Therapeutics reported the following: "On September 20, 2022, United Therapeutics Corporation (the Company) announced the termination of the PERFECT clinical study evaluating Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with chronic … [Read more...] about United Therapeutics stops Phase 3 PERFECT trial of Tyvaso inhalation solution in PH-COPD patients

Synairgen announced that it will present data from the Phase 3 SPRINTER trial of its SNG001 nebulized interferon-beta-1a in hospitalized COVID-19 patients at an upcoming meeting showing that treatment with SNG001 reduced symptoms of long COVID at 60 and 90 days post treatment compared to placebo. According to the data provided, patients treated with SNG001 had a 28.3% … [Read more...] about Synairgen to present data showing its SNG001 nebulized interferon-beta-1a may reduce the risk of long COVID symptoms

Satsuma Pharmaceuticals announced that data from a portion of the Phase 3 ASCEND trial of the company's STS101 dihydroergotamine (DHE) nasal powder where STS101 was delivered via a second generation device for the treatment of migraine did not reveal any significant safety concerns. Satsuma also said that efficacy was improved when subjects used the new device … [Read more...] about Satsuma announces data from the Phase 3 ASCEND trial of STS101 DHE migraine using second generation nasal delivery device